
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is poised for strong long-term growth due to its innovative and effective treatment for obstructive sleep apnea in a large and growing market. The company's positive first quarter results, with strong revenue and profitability despite headwinds from reimbursement changes and coding disruptions, demonstrate the resilience and potential of the business. However, near-term uncertainties and competition may limit growth in the short term, leading to a cautious "hold" recommendation from analysts.
Bears say
Inspire Medical Systems is facing significant challenges in the short term, with uncertainties surrounding reimbursement coding and potential competition from new neurostimulation devices in the obstructive sleep apnea market. These challenges have led to a significant decrease in the company's revenue guidance for 2026, and it may take several quarters for Inspire to turn the business around. While the company's technology and market position are still attractive, the ongoing reimbursement situation and potential impact from GLP-1 therapies on patient funnel growth are cause for concern. As a result, our outlook is negative and we have downgraded the stock to Neutral with a price target of $55, based on the assumption of 1x our FY27 revenue estimate.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares